Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Voorraadrapport

Marktkapitalisatie: US$10.6b

Sarepta Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Sarepta Therapeutics heeft een totaal eigen vermogen van $1.2B en een totale schuld van $1.2B, wat de schuld-eigenvermogensverhouding op 100.5% brengt. De totale activa en totale passiva bedragen respectievelijk $3.6B en $2.4B. De EBIT Sarepta Therapeutics is $81.0M waardoor de rentedekking -6.6 is. Het heeft contanten en kortetermijnbeleggingen van $1.2B.

Belangrijke informatie

100.5%

Verhouding schuld/eigen vermogen

US$1.23b

Schuld

Rente dekkingsratio-6.6x
ContantUS$1.20b
AandelenUS$1.22b
Totaal verplichtingenUS$2.38b
Totaal activaUS$3.60b

Recente financiële gezondheidsupdates

Recent updates

Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 13
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

The Play On Sarepta Therapeutics

Sep 26

Sarepta Therapeutics Muscles Up In DMD Race

Sep 19

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Jul 24

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05
Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 17

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

May 08
Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05
Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Apr 15
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 11

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Dec 20
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Nov 29
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Aug 08
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Apr 30
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $2.7B ) SRPT } overtreffen de korte termijn passiva ( $699.5M ).

Langlopende schulden: De kortetermijnactiva SRPT ( $2.7B ) overtreffen de langetermijnschulden ( $1.7B ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 2.4% ) SRPT wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van SRPT is de afgelopen 5 jaar gestegen van 43.9% naar 100.5%.

Schuldendekking: De operationele kasstroom van SRPT is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: SRPT verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.


Balans


Ontdek gezonde bedrijven